These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 25795777

  • 1. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
    Wright CM, van der Merwe M, DeBrot AH, Bjornsti MA.
    J Biol Chem; 2015 May 08; 290(19):12068-78. PubMed ID: 25795777
    [Abstract] [Full Text] [Related]

  • 2. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
    Alessandri M, Beretta GL, Ferretti E, Mancia A, Khobta A, Capranico G.
    J Mol Biol; 2004 Mar 19; 337(2):295-305. PubMed ID: 15003448
    [Abstract] [Full Text] [Related]

  • 3. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
    Scaldaferro S, Tinelli S, Borgnetto ME, Azzini A, Capranico G.
    Chem Biol; 2001 Sep 19; 8(9):871-81. PubMed ID: 11564555
    [Abstract] [Full Text] [Related]

  • 4. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
    Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P.
    Mol Pharmacol; 1999 Dec 19; 56(6):1105-15. PubMed ID: 10570037
    [Abstract] [Full Text] [Related]

  • 5. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
    van der Merwe M, Bjornsti MA.
    J Biol Chem; 2008 Feb 08; 283(6):3305-3315. PubMed ID: 18056711
    [Abstract] [Full Text] [Related]

  • 6. Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.
    Palle K, Pattarello L, van der Merwe M, Losasso C, Benedetti P, Bjornsti MA.
    J Biol Chem; 2008 Oct 10; 283(41):27767-27775. PubMed ID: 18693244
    [Abstract] [Full Text] [Related]

  • 7. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
    D'Annessa I, Tesauro C, Wang Z, Arnò B, Zuccaro L, Fiorani P, Desideri A.
    Biochim Biophys Acta; 2013 Dec 10; 1834(12):2712-21. PubMed ID: 24096022
    [Abstract] [Full Text] [Related]

  • 8. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.
    Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA.
    Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):13767-72. PubMed ID: 14585933
    [Abstract] [Full Text] [Related]

  • 9. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
    Sirikantaramas S, Meeprasert A, Rungrotmongkol T, Fuji H, Hoshino T, Sudo H, Yamazaki M, Saito K.
    Phytochemistry; 2015 May 25; 113():50-6. PubMed ID: 25733498
    [Abstract] [Full Text] [Related]

  • 10. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
    Bjornsti MA, Knab AM, Benedetti P.
    Cancer Chemother Pharmacol; 1994 May 25; 34 Suppl():S1-5. PubMed ID: 8070016
    [Abstract] [Full Text] [Related]

  • 11. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
    Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti MA, Benedetti P.
    J Biol Chem; 2007 Mar 30; 282(13):9855-9864. PubMed ID: 17276985
    [Abstract] [Full Text] [Related]

  • 12. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay.
    Stewart L, Ireton GC, Champoux JJ.
    J Biol Chem; 1999 Nov 12; 274(46):32950-60. PubMed ID: 10551862
    [Abstract] [Full Text] [Related]

  • 13. Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.
    Hann CL, Carlberg AL, Bjornsti MA.
    J Biol Chem; 1998 Nov 20; 273(47):31519-27. PubMed ID: 9813066
    [Abstract] [Full Text] [Related]

  • 14. Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.
    Viard T, Cossard R, Duguet M, de La Tour CB.
    J Biol Chem; 2004 Jul 16; 279(29):30073-80. PubMed ID: 15140883
    [Abstract] [Full Text] [Related]

  • 15. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM, Pommier Y.
    Biochemistry; 2002 Feb 05; 41(5):1428-35. PubMed ID: 11814334
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, Collod-Beroud G, Coquelle A, Pasero P, Pourquier P, Martineau P, Del Rio M.
    Mol Cancer; 2011 May 27; 10():64. PubMed ID: 21619602
    [Abstract] [Full Text] [Related]

  • 18. Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin.
    Ireton GC, Stewart L, Parker LH, Champoux JJ.
    J Biol Chem; 2000 Aug 18; 275(33):25820-30. PubMed ID: 10827183
    [Abstract] [Full Text] [Related]

  • 19. Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.
    Siu FM, Pommier Y.
    Nucleic Acids Res; 2013 Dec 18; 41(22):10010-9. PubMed ID: 24021629
    [Abstract] [Full Text] [Related]

  • 20. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.
    Knab AM, Fertala J, Bjornsti MA.
    J Biol Chem; 1995 Mar 17; 270(11):6141-8. PubMed ID: 7890748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.